The failure of anti-PD-1/PD-L1 immunotherapies to sustain durable response in many lung cancer patients emphasizes the need to delineate tumor cell-intrinsic and tumor microenvironment resistance mechanisms, characterize biomarkers for patient selection, and develop rational combinatorial therapeutic strategies. The gene discussed is CD274; the disease is neoplasm.